List of Biotech, Pharmaceutical & Life Sciences companies in Washington - 250

We are North America's premier HLVd testing company and tissue culture licensing technology all over the US and world. From Washington to Germany, we are here to help cultivators de-risk their operations, scale their production safely, and reap the benefits of this exciting crop. Almost every clonally-produced crop has moved to tissue culture plant starts for a reason. Plants that are starting disease-free tend to be highly vigorous throughout their life cycle and focus more energy on growth and secondary metabolite production, augmenting the performance of the crop and economic return. We work with established breeders in every region to ensure that our genetics will keep you compliant and help you succeed where you grow.

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

Absco Therapeutics, Inc. (AbscoTx) is a stealth phase immune engineering company born out of collaborative work between clinicians at MGH and BWH, engineers at MIT, and an experienced team of biotech entrepreneurs and translational medicine experts.

ABT 360 manufactures media for embryo transfer. The media is used to collect, store and transfer embryos from cattle and horses and is used for the veterinary assisted reproduction industry.

Like it's predecessor, the Infectious Disease Reseach Institute (IDRI), the Access to Advanced Health Institute (AAHI) focuses on creating technologies that improve the body's response to disease.AAHI is a nonprofit biotech organization that works on a comprehensive approach to developing new solutions for infectious disease.

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.

ActX, Inc. is a dynamic venture that is focused on making patient genomic information truly useful in everyday medical practice. We are currently seeking a Linux System Administrator/DevOps Specialist to work in a unique, small team environment where innovative new processes assist everyone's productivity. Join our team and help us make personalized medicine a reality rather than a dream!

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

We're thrilled to announce the launch of Adecco Search- The solution you need when your business seeks permanent, mid-level and leadership talent. To learn more, please reach out to your local Adecco representative or visit: https://tinyurl.com/yx9awhyx

Advanced Cellular Dynamics (ACD) is a world-leader in the production, provision and application of novel cell-based assay systems. Our capabilities provide us with a unique capability to explore a variety of biological entities and systems. We have deep-rooted expertise in kinases, GPCRs, ion channels and transcription factors - to name a few. Those skills are applied to a variety of experimental systems that include (but aren't limited to) oncology, immunology and neurobiology. We also leverage these skills to provide our global clientele with contract research services. Whether you want to disrupt a specific gene in stem cells, or create a new biological cell-based assay in your tissue/cell line of choice, we have the knowledge and skills to help you succeed!

Founded by Dr. Elizabeth Ruzzo, adyn is helping people find birth control without side effects based on a person's genetic risk and hormone profile. Despite the 47M birth control users in the US, virtually no studies examine the biological factors that explain why individuals respond differently to a given contraceptive method. Launched in May 2022, The Birth Control Test is the first test designed to prevent birth control side effects. While we are improving the birth control experience, we are also committed to closing the gender health gap. By partnering with individuals, adyn leverages personal preference, medical history, and biological data to proactively help every (unique) body select the most desirable birth control option – with the least dangerous side effects. Our vision is to be earth's most inclusive and patient-centric personalized medicine company. When a person uses The Birth Control Test, they can opt in as an anonymous research participant to help close these research gaps. This means you can simultaneously find the right birth control for your body, while helping others do the same.

AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics (using mammalian and microbial systems), mRNA, pDNA, viral vector and cell therapy products, from pre-clinical to commercial production, including our proprietary CHEF1TM Expression System for efficient protein production with CHO cells. Our company DNA drives us to provide innovative solutions to partner with our customers in helping them reach their goals and accelerate their projects at our cGMP-compliant facilities in the US, Europe and Japan, as well as to facilitate approval and manage spending during the product lifecycle. We forge exceptionally strong partnerships with our customers and we never lose sight of our commitment to deliver reliable and compliant drug substance. Visit www.agcbio.com to learn more.

We help entrepreneurs form new teams and build AI-first startups. Apply on our website for $500k investment, up to $1M in free AI compute, and network of AI founders and researchers. We bring together world-class engineers, researchers, and entrepreneurs to create new companies together from scratch. From ideation to execution, we help generate ideas, find co-founders, secure pilot customers, integrate cutting-edge AI, and more. Our hands-on support guides founders through building, scaling, and raising millions in venture funding. In 6 years, we've backed 40+ companies now valued at $1B+, raising $220M+ and creating 700+ jobs. Our startups are transforming industries: improving immigrant communication (Yoodli), accelerating cancer research (Ozette and Modulus), enhancing legal efficiency (Lexion, acquired by DocuSign), turning smartphones into medical devices (PreemptiveAI), and so much more. Any VC can write a check, but what truly sets us apart is our unparalleled technical and AI expertise. With our heritage at the Allen Institute for AI—founded by Microsoft co-founder Paul Allen—we’ve been singularly focused on commercializing AI long before it became a buzzword. AI2 has 200+ PhDs, researchers, engineers, professors, and support staff—and is well known for its contributions to the A.I. research community including 600+ papers, 20+ best paper awards, and numerous products/open-source offerings including SemanticScholar, AllenNLP, and more. Our core team includes pioneers like Oren Etzioni, a leader in AI for over three decades, and our deep technical expertise means we don’t just back you financially—we help you build breakthrough products, navigate complex challenges, and accelerate your company’s growth. We're soon launching AI House in Seattle, a central hub for AI innovation. In partnership with the Mayor of Seattle and supported by Washington state, this space will serve as a central hub for the region’s AI community.

A.I. Analysis, Inc. is a medical software company specializing in the application of artificial intelligence (AI) to radiology. A.I. Analysis, Inc.’s first product is the Change Detector for Brain Imaging, a machine-learning based system that compares serial MR imaging studies and presents changes in the form of a color overlay superimposed on the anatomical images. The Change Detector saves radiologists time at the beginning of their reading — perhaps up to 10 minutes for diseases such multiple sclerosis. The Change Detector highlights the locations of changes and degree of those changes, so the radiologist can more quickly reach clinical judgments. Using the Change Detector, it may be possible for radiologists to detect changes months earlier than is possible with manual inspection alone, with greater reproducibility.

Aiberry is an AI-powered multimodal platform that offers providers and care managers rapid, objective, and unbiased behavioral health assessments. Aiberry delivers evidence-based insights virtually (in telehealth scenarios) and at the point of care, offering unique outreach and scale opportunities.

Aigen is accelerating the transition to regenerative agriculture. We're launching the world's first AI-driven, network connected robotic fleet, powered entirely by the elements. Aigen is building a future with no harmful chemicals in our food. Backed by NEA, GFC, AgFunder, Regen.vc, and Bessemer Ventures

Algomedix is an emerging biotechnology company which is using the advances in precision medicine to accelerate drug discovery and development for TRP (Transient Receptor Potential) targeted therapeutics. Critical members of the large TRP superfamily include TRPA1, which is a validated target recognized by the pharmaceutical industry for the discovery and development of novel therapeutics to treat pain, inflammation, ocular and dermatological disease. Algomedix has successfully identified novel small molecules that target human TRPA1 with both high potency and specificity, and have been optimized to have excellent drug-like properties. Thus, the Algomedix compounds represent a major advance in next-generation pain killers which have no opioid related, NSAID related, or gabapentanoid adverse effects, and have been rationally designed to have no addiction or abuse liabilities. These advantages are further enhanced by a primary peripheral mechanism of action, blocking pain at its source. Algomedix possesses near-term clinical development opportunities combined with novel approaches to developing its first-in-class novel therapeutics addressing a critical unmet medical need. Algomedix's most advanced patented compound is in late-stage preclinical development and prepared to advance to clinical trials. This compound has demonstrated potent analgesic activity activity in multiple established pain models, which are recognized as the gold standards in the areas of osteoarthritis pain (OA), neuropathic pain, and chemotherapeutic-induced peripheral neuropathy. Due to the critical and fundamental role of TRPA1 in mediating the initial steps of pain signaling throughout the body, there are multiple therapeutic applications for treating chronic and acute pain in patients. In addition, Algomedix is pursuing programs developing a pipeline of novel, first-in-class molecules for other indications, which include chronic kidney disease and cardiac hypertrophy

Allele Diagnostics, Inc., located in Spokane, WA, was established in 2014 to offer superior genetic testing services. We feel that high-quality testing, reporting, and services can be offered to you with quick results. We pride ourselves in being a laboratory that offers the genetic counseling services clinicians need in a genetic testing company. We combine this service with reliable, fast, accurate test results provided to you via user-friendly and conveniently accessible reports. At Allele Diagnostics, we are passionate about providing reliable answers as quickly and accurately as possible. We continuously strive to improve the efficiency of our workflow and improve the quality of our test results. We encourage feedback from our clients on how we can improve or assist in bringing your ideas into a clinical testing environment. Utilizing our extensive experience in genetic testing, we can work with you to develop solutions to the challenges you have previously experienced in receiving fast, accurate results. Additionally, we are always looking for new and better ways to provide answers to genetic questions and are continuously evaluating novel technologies to see how they can fit into our laboratory given the rapidly evolving clinical genetic testing space. Allele Diagnostics is a CLIA and CAP certified clinical laboratory committed to providing superior testing services for the best patient care possible. We are currently licensed in California, Florida, and Pennsylvania and are pursuing various other state specific licenses.

The mission of the Allen Institute is to unlock the complexities of bioscience and advance our knowledge to improve human health. Using an open science, multi-scale, team approach, the Allen Institute focuses on accelerating foundational research, developing standards and models, and cultivating new ideas to make a broad, transformational impact on science. Founded by philanthropist and visionary Paul G. Allen, the Allen Institute is a recognized leader in large-scale, open science research. Its research institutes include the Allen Institute for Brain Science, Allen Institute for Cell Science, Allen Institute for Immunology and The Paul G. Allen Frontiers Group. The Allen Institute believes that team science significantly benefits from the participation of diverse voices, experiences and backgrounds. High-quality science can only be produced when it includes different perspectives. We are committed to increasing diversity across every team and encourage people from all backgrounds to apply for our open positions.

Alli Connect is a mental health care service for first responders that proactively promotes wellness and positive change in public safety.

Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical focused on rare diseases with high unmet needs. We are developing first-in-class therapeutic peptides with multiple biological actions, including anti-fibrotic, anti-inflammatory, cell regenerative, and beneficial metabolic effects that provides development opportunities across multiple diseases. Our lead drug, ALY688ER, an extended release formulation designed for extended delivery of ALY688 throughout the body, is a potent and specific activator of adiponectin signaling pathways. Adiponectin is a beneficial cytokine produced mainly by adipose cells and which protects against obesity-associated diseases. ALY688 is the first adiponectin receptor agonist to enter human testing. Our lead indication is Duchenne muscular dystrophy (DMD), a serious rare genetic disease of boys in which muscle tissue damage due to muscle cell injury, inflammation and replacement of muscle by fibrotic tissue results in progressive loss of skeletal muscle function. In relevant animal DMD models, ALY688 reduced muscle cell death, enhanced muscle regeneration, and reduced inflammation and fibrosis, resulting in preservation of muscle strength and endurance. In addition, ALY688 has shown similar benefits across a range of other inflammatory and fibrotic conditions potentially expanding its use in additional indications.

Altius Institute for Biomedical Sciences is an independent, nonprofit research organization created to pursue discovery at the leading edge of modern biomedicine. Enabled by a visionary founding investment from GlaxoSmithKline, Altius is creating a new paradigm to catalyze ground-breaking biological innovation, integrate molecular and computational science and engineering, and empower fundamental technology development to radically accelerate the leap from basic to medical breakthroughs. Altius is pioneering a new framework for conceiving, executing and sharing rapidly-moving science by replacing traditional hierarchies and silos with a networked organization that maximizes discovery through synergy. We are now expanding our team of talented computational scientists with experience in machine learning, data visualization and information design. In addition, we are looking for outstanding postdoctoral researchers with － computational and/or experimental － experience in genomics research. These Altius Fellows will be provided with exceptional resources, operational and salary support, and mentorship to pursue groundbreaking interdisciplinary research at the leading edge of genome biology.

AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach. Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.

Amplicon independently validates all COVID19 IgM/IG Rapid Tests offered. In business since 1996, Amplicon proactively performs investigational research to confirm the claims of all manufacturers. Doing our due diligence is a critical part of bringing the best performing tests to Medical Professionals. To learn more, please visit https://covid19.ampliconexpress.com/

Ananta has developed a centrifugal fluidized expansion (CentriFLEX) perfusion bioreactor that balances centrifugal forces with a continuous feed of fresh media. The CentriFLEX resolves a key manufacturing bottleneck in continuous cell culture. This instrument supplies fresh media, removes inhibitory cell waste, and prevents the loss of cell products.

We are experienced scientists, engineers, and business people working together to tackle a global challenge: detecting infection with COVID-19. Together, we are determined to help save lives by delivering rapid, precise, and inexpensive diagnostic tests. Our goal is to enable health care professionals to confidently provide lab-quality results in minutes instead of days so that patients can ​confidently know almost immediately whether they are positive -- or not. Our first product, The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector, is designed to provide a precise diagnosis of COVID-19 in under 30-minutes (on average) instead of the 1-3 days that most testing services and physician offices now require for PCR testing. Using our patent-pending proprietary technologies, the AscencioDx diagnostic test is administered painlessly, in just seconds, with a lower-nasal swab. Our mission is to continue developing and marketing diagnostic test systems for diseases in addition to COVID-19 using our PCR- equivalent point-of-care diagnostic platform without the unnecessary delay, expense, or reliance on less-than-precise antigen testing. This is only the beginning. *The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector have not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The Applied Physics Laboratory at the University of Washington serves both undergraduate and graduate students as they learn to conduct research within one of the eight departments:AcousticsAir-Sea Interaction and Remote SensingCenter for Environment & Information SystemsCenter for Industrial & Medical UltrasoundElectronic & Photonic SystemsOcean EngineeringOcean PhysicsPolar Science Center

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.

Aquatactics provides the following services related to fish health: Fish Health Products Veterinary + Regulatory Consultation Pathology Services Fish Health Education + Stockmanship Training Vaccination Protocol Design

Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Arzeda combines protein design, pathway design, HT screening and strain construction to create and improve designer fermentation strains for virtually any chemical. One example of their work is indeveloping new and improved enzymes to make rare sugars, natural sweeteners,and other oligosaccharides.

Aseptica is a medical device development company focused on EDTA related products.

AstaReal produces astaxanthin from algae and is part of the AstaReal Group which is a wholly-owned subsidiary of Fuji Chemical Industries Co., Ltd.

At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer’s, so that patients can regain their memories, lives, and family relationships.

Founded in 2019, Atomo is a Seattle-based, food-tech startup improving coffee taste and confronting the climate crisis by reinventing coffee for tomorrow. They have reverse-engineered the coffee bean—producing outstanding espresso that tastes great and does good.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis

AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 triggers the production and release of endogenous gamma delta+ Natural Killer T cells and could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology. The company is committed to developing products that improve outcomes without additional suffering because side effects from treatments should never be worse than the diseases themselves.

Beta Hatch is industrializing insect agriculture within a regenerative food system. We make protein for plants and animals in a zero waste system using at our mealworm ranch in Cashmere, WA. Our circular production system uses waste heat from a neighboring data center to condition our insect grow rooms, in collaboration with the Washington Clean Energy Fund.

Research & Diagnostic Products. Bio-Rad is partnering with Biodesix on a test for SARS-CoV-2.EUA (05/2020) for a digital PCR molecular diagnostic test for SARS-CoV-2, the virus that causes coronavirus disease COVID-19. The 2019-nCoV CDC ddPCR Triplex Probe Assay is now authorized for use on the firm's QX200 and QXDx Droplet Digital PCR systems.

BioViva USA is dedicated to improving healthy human longevity through bioinformatics. The Biovault bioinformatics platform is contributing to health predictions and recommendations, precision medicine, and the discovery of novel biomarkers by applying state of the art computational methods on vastcollections of biological data.BioViva is partnered with Integrated Health Systems (IHS). IHS is an innovative company specializing in cell and gene therapy, aprivate care company supporting health professionals working with groundbreaking treatments and therapeutics to support healthy longevity. Theywork exclusively with regenerative medicine specialists targeting the aging process.BioViva is committed to:Bridging stakeholders with biotechnologyFacilitating the development of treatments and therapeutics through the BioViva platform, designed to be readily browsable by longevity researchers.Accelerating the path to human trials for life-saving gene therapies.Providing biotechnology companies, medical researchers, and patients access to one another, expediting research and development.The Biovault will continuously update user profiles, including changes in relevant biomarkers. BioViva is utilizing the latest machine learning algorithms to formulate hypotheses and validate findings, thereby paving the way for optimal combinatorial regimens addressing the root causes of the aging process.

Blaze Bioscience, Inc. is a privately held biotechnology company dedicated to improving the lives of cancer patients, starting with kids undergoing brain cancer surgery. By leveraging our Tumor Paint technology®, including the CANVAS Imaging system® and our CDP Discovery Platform, our goal is to make the detection, removal, and treatment of all cancers sensitive, reliable, and accessible, especially early-stage cancers where cure may still be possible.

Bloodworks Northwest is an independent, community-based nonprofit organization with a tradition blending volunteerism, medical science, education and research to advance transfusion medicine and improve patient care. A recognized leader in transfusion medicine, Bloodworks serves patients in nearly 90 hospitals and clinics in the Pacific Northwest and provides tissue and transplantation support to 185 hospitals across the Northwest. Patients with leukemia, cancer, burns, hemophilia and traumatic injuries also depend on Bloodworks research. With your help, we're bettering our community drop by drop.

Blue Heron has been collaborating with some of the most brilliant minds in the industry to create millions of complex genes using our proprietary GeneMaker® multi-technology platform. We are the first gene synthesis company founded and solely operated in the USA. Our only location in Bothell, Washington subjects us to strict U.S. standards for Intellectual Property (IP) Policy and ensures every contract for each customer is confidential. Because of our simple flat rate pricing, we deliver what no other company can provide — the assurance your project will proceed as quoted. Utilizing high grade reagents and proprietary technology we produce DNA of the utmost quality. Our aptitude for projects involving unusually long or difficult sequences allows clients to eliminate errors, risk, and costs that are simply no longer a necessary part of the research process. Blue Heron Provides: - Dedicated Customer Service - Simple Pricing - Easy Ordering - Strict Client Confidentiality - Guaranteed Turnaround Time - Sequence Design - Synthesis of Genes up to 50KB - Complex Genes (hairpins, repeats) - 100+ IP free Expression Vectors - Free Codon Optimization - Free Archiving Publications Citing Blue Heron Biotech Gene Synthesis: http://www.blueheronbio.com/assets/documents/citations/BlueHeronBiotechCitations.pdf

Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.

Brooks Applied Labs was formed in 2015 through the merger of the two industry-leaders in the field of specialty trace metals analysis and metals speciation: Brooks Rand Labs & Applied Speciation and Consulting. Today, Brooks Applied Labs provides Meaningful Metals Data and Advanced Speciation Solutions to hundreds of projects worldwide, and we are very dedicated to staying in our niche. Many members of our staff, from the Sample Disposal Technician to our CEO, are seasoned veterans in the world of ultra-trace metals analysis and metals speciation. Together we work to provide thoroughly ultra-clean and pre-tested sampling equipment, fast turn-around-time options, high-quality validated data, and custom reporting packages at competitive prices to ensure that our clients receive the data and consulting they require to make critical decisions.

Cadence Biomedical, a commercial-stage medical device company headquartered in Seattle, Washington, is committed to working with healthcare professionals, patients and caregivers to advance neurorehabilitation. The company's primary commercial product, Kickstart®, is a neurorehabilitation device designed to accelerate a recovery to walking in stroke, multiple sclerosis, spinal cord injury patients and in individuals with other progressive neurological conditions. Kickstart is available for use in physical therapy during the initial recovery process and as a prescribed device for post-discharge use in the community and home settings. For more detail, please see www.cadencebiomedical.com.

Cadence Neuroscience is developing a fundamentally new approach to neuromodulation, starting with a therapy to treate severe epilepsy.

Cancer Research And Biostatistics (CRAB)® is a non-profit organization whose mission is to help conquer cancer, and other diseases. Since 1997, CRAB has supported over 300 clinical trials in partnership with foundations, universities, pharmaceutical and biotech companies. Past project experience has ranged from phase I to phase III, registration, staging, and prevention trials. CRAB provides a constellation of services that can help with concept creation, trial conduct, and regulatory submission or publication. Dr. Antje Hoering serves as President and CEO. Dr. John Crowley, co-founder with Dr. Cay Crowley, is Chairman of the Board of Directors. CRAB believes that collaboration accelerates outcomes. CRAB has long-standing partnerships with several cancer research organizations, including the SWOG Cancer Research Network, The Hope Foundation for Cancer Research, and SWOG Clinical Trials Partnerships. SWOG is one of five National Cancer Institute (NCI) supported members of the National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP). CRAB and Fred Hutchinson Cancer Research Center make up the SWOG Statistics and Data Management Center (SDMC). CRAB is also an integral collaborator with the International Association for the Study of Lung Cancer (IASLC) since the late 1990s, publishing analysis for over 200,000 lung cancer cases in the 7th and 8th editions of the Staging Manuals. CRAB currently serves as the Independent Analysis Center for Friends of Cancer Research's ctDNA for Monitoring Treatment Response (ctMoniTR) Project. In this project, CRAB receives data from the pharmaceutical and diagnostic partners, coordinates input from collaborators, harmonizes and pools data, and analyzes the pooled data to meet the project's objectives. Message us to learn how we can support you in your next clinical trial, or partner with you, to continue to make strides in preventing and curing cancer.

CancerTargetedTechnology develops innovative agents for cancer that accurately detect early and advanced disease, monitor treatment efficacy

Capsigen is a leader in the engineering of AAV capsids for use in gene therapies, opening the path to permanent cures for patients suffering from intractable illness. Capsigen is enabling a new era of genetic medicines based on a disease-first approach. Powered by our TRADE™ and data science platforms, we engineer vectors with the highest possible potency and cell-type specificity. Developing genetic medicines that are tailored to the unique biology involved in the disease ensures that the therapy can bring the maximum benefit to patients. Our team is driven in its pursuit to deliver on this promise to the millions of people depending on the advancement of science to discover new cures.

Cardiac Insight, Inc. is a privately held medical device company based in Seattle, Washington, renowned for its Cardea SOLO ECG system. With FDA clearance since 2017, this tool provides comprehensive cardiac evaluations, comfortably worn over seven days. Dr. Dave Hadley and Dr. Vic Frolicher, creators of the Cardea 20/20 ECG, introduced a proprietary handheld 12-lead ECG device that enhances electrocardiogram reliability for detecting cardiovascular issues in young athletes, transforming athletic heart care. The Cardea 20/20 ECG incorporates breakthrough interpretive algorithms and international criteria, enabling swift identification of complex cardiac abnormalities leading to Sudden Cardiac Arrest (SCA). In 2021, Cardiac Insight joined forces with global electronic components leader Dreamtech, solidifying its position as a leading innovator in cardiac healthcare diagnostics, poised for exponential growth.

The Cascadia Drug Development Group was founded by seasoned industry experts who are passionate about immunology and drug development. CDDG provides strategic advisory support, including indication prioritization and investment opportunity diligence, as well as planning and tactical oversight of therapeutic development activities. Importantly, we help integrate quality decisions into programs early and focus on efficiently bridging the gap between discovery, lead generation and initial clinical proof of concept. By offering a flexible and virtual structure and leveraging an externalized research model, we easily adapt to client and project needs to reduce overall costs. Our aspiration is to provide the highest quality approach to drug development that maximizes the value of excellent therapeutic opportunities around the globe.

Medical device company innovating a patent-pending device to provide safety with indwelling urinary catheters.

CellNetix Pathology & Laboratories is a dynamic, rapidly growing private pathology company headquartered in Tukwila, WA, and serves hospitals and clients throughout the greater Puget Sound region. CellNetix provides comprehensive subspecialty clinical and anatomic pathology services, operates premier anatomic pathology laboratories, and offers complete pathology laboratory services at its central state-of-the-art anatomic pathology laboratory. CellNetix is known for pathologic excellence based upon pathologist subspecialization, for valuing intellectual capital at all levels of the company, and for delivering top-quality results. CellNetix is composed of more than 65 pathologists and 300 total employees. With our size, economies of scale, resources, and volume of referral material, we have created a centralized, state-of-the-art anatomic pathology laboratory leveraging best-in-class information technologies and equipment and lean process design. CellNetix has attracted highly talented professional, technical, and business leaders who provide each individual clinician and patient with focused, personal service. CellNetix believes that local pathologists partnering with local clinicians and hospitals results in the best possible patient care. We use the extensive expertise of our pathologists and laboratory personnel to bring that level of care to each and every patient.

Founded in 2015, Cerevast Medical, Inc. is a clinical-stage medical device company based in Bothell, Washington, USA. Leveraging our core expertise in the fields of ultrasound and microsphere technologies, we are committed to developing novel, first-in-class therapeutic solutions to restore health and improve the quality of life for patients that suffer from major diseases.

Chondrex, Inc. has been shaping the landscape of arthritis and inflammation research worldwide since 1996. Chondrex was initially focused on providing scientists with the tools necessary to study the pathogenesis of Rheumatoid Arthritis (RA) as well as to develop and screen potential therapeutics for RA. Over the past 20 years however, our scope has expanded beyond just RA research. We now offer a plethora of products ranging from collagen and monoclonal antibody reagents to a wide variety of assay kits for use in allergy, arthritis, connective tissue, and nephritis related research. One such product line, the Collagen Antibody-Induced Arthritis (CAIA) cocktails, allows for faster and more consistent dosage dependent induction of arthritis in mice than the Collagen Induced Arthritis (CIA) model. Furthermore, the CAIA model can be induced in almost all strains of mice, (including CIA-resistant, T-cell deficient, gene knockout, and transgenic mice) whereas the CIA model requires a restricted haplotype. Chondrex is committed to providing the highest quality and most reliable products in order to accelerate the rate of discovery in arthritis and inflammation research.

For over 30 years, CID Bio-Science, Inc. has been designing instruments for agricultural and environmental research. We specialize in creating light, compact tools that are fully functional on-site. Our instruments provide data on demand with no need for lab analysis with research applications including: photosynthesis, canopy analysis, leaf area, spectroscopy, and root function. CID is made up of engineers, scientists, assemblers, machinists, technicians, and businesspeople who have dedicated our careers to building tools for plant physiology research. Our Application Scientists and Sales staff work directly with science and agricultural professionals to equip them with the instruments that will best meet their needs. After decades of engineering tools for plant science, our subsidiary company, Felix Instruments-Applied Food Science, is providing a new line of sensing tools for commercial post-harvest applications. Visit www.felixinstruments.com to learn more. Headquartered in Camas, Washington in the United States, CID is represented by distributors in 44 countries around the world and is an expert in developing new global markets. - The WA Department of Commerce, nominated the company which was awarded the 2011 World Trade Center Exporter of the Year award. - In 2010, CID was awarded both Washington State and Northwest regional SBA Exporter of the Year awards. - In October 2011, CID Bio-Science commenced a $1.5M renovation of a historic property in downtown Camas, WA which will serve as the permanent home for their expanding operations. Committed to the public good, CID considers our customers, distributors, vendors and public community in each of our actions. CID Bio-Science is proud to be a U.S. manufacturer—designing and assembling all products in Camas, Washington, USA, and supporting fellow businesses by sourcing materials locally whenever possible.

CisThera Inc. is a privately owned biopharmaceutical company in the Seattle area. CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases. CisThera is taking a novel approach to identify drugs with greater efficacy that broadly inhibit validated contributors to disease pathogenesis.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Compliment Corporationis a start-up biotechnology company developing revolutionary therapeutics in oncology. Ourmission is to improve cancer treatment by dramatically increasing the effectiveness of cancer drugs and by reducing the toxicities associated with standard chemotherapy treatment.

Tianjin Conjustar Biotechnology Co., Ltd. is a researcher and developer of peptide-drug conjugate intended for oncology treatments. The company was established in early 2022 and is located in Tianjin Airport Free Trade Zone. It was founded by Fosun Health Capital and focuses on cooperative development and independent research.

Cordant was founded in 1959 by the Ullmann family. Starting with security services, we soon became experts in the delivery of flexible solutions to meet the changing needs of our clients. The business grew, and we began offering other services such as multi-sector recruitment, healthcare, cleaning and more recently technical facilities management. Sixty years later, and we employ around 125,000 staff each year, most of which undertake work for over 5,000 client organisations. We operate internationally, across a broad and diverse range of specialisms, although we've grown, our strong family foundations mean that we've stayed connected to our employees, clients and suppliers, and to the communities we operate in. As pioneers in the recruitment and facilities space, our industry-leading services allow us to take care of people and property so clients can focus on their core business. We're about more than a service transaction - we're about helping thousands of people to live good lives. We're building a stronger society by welcoming a new era of positive impact, shared values and enhanced cooperation. In 2017, we took the natural next step: we became a social business. We're proud to be the biggest business in the UK using purpose to drive meaningful profit and to be amongst a group of forward-thinking companies who are using business to improve society.

Cramer Fish Sciences (CFS) is an employee owned fisheries research consulting firm with offices in Oregon, California, Idaho and Washington. Established in 1987, CFS provides a fantastic work environment that fosters growth and learning in a casual yet productive atmosphere. Our mission is to rigorously apply the scientific method to afford our clients innovative, scientifically robust solutions to address a variety of fisheries and environmental challenges. The CFS team achieves these high standards through effective and unbiased data collection, insightful analysis and interpretation, and clear communications. Visit our website at www.fishsciences.net.

Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Cuervo's goal is to rapidly advance innovative new vaccine candidates from the research laboratory to the clinic by joining forces with the South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.

CurvaFix is developing implantable products to improve fracture repair in curved bones. The company is focusing on Fragility Fractures of the Pelvis (FFP) and high-impact pelvic fractures. The CurvaFix® IM Implant is the only intramedullary device capable of following the natural bone shape and filling the space within curved bones such as the pelvis.

Cyrus Biotechnology is a biotechnology company that specializes in protein engineering and drug discovery through computational biology.

CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.

We apply modern methods in agricultural biochemistry and genetics to dramatically improve cannabis varieties. These improvements ensure an unmatched experience for the cultivator and consumer alike.

Founded in 1987, DiagnosTechs™ is a pioneer and leader in saliva-based testing. Our commitment to assisting healthcare professionals in restoring patients'​ health and wellness is unsurpassed with over 1.2 million specimens tested per year. Saliva testing is a powerful tool for evaluating stress, hormone-related disease and health conditions, especially over time. DiagnosTechs continually improves and refines its laboratory testing standards, using cutting-edge technology and methods. Many healthcare providers and their patients have chosen DiagnosTechs as their partner in wellness.

DMXi makes oral care products based on peptides derived from the Amelogenin protein. Their products are designed to strenghen, desensitize, and brighten teeth.

Downstream Therapeutics is a biotechnology company that focuses on developing a combination drug-device to reduce cell injury after restoration of blood flow.

Engineering and Design of Implantable Medical Devices We are the industry leader in Engineering and Design of implantable medical devices and have helped many companies through the product development and regulatory approval process. ECHOBIO LLC has over 18 years of experience with medical devices including self-expanding and balloon expandable stents, stent grafts, heart valves and others, as well as a strong background in implantable materials (metals, polymers, ceramics and biomaterials). This experience provides a solid foundation for using FEA and improves our simulation of devices and surgical procedures. We participate on international standards committees and pioneer innovative materials research to develop better engineering methods for making safe and reliable implantable medical devices. Our goal is to put our engineering and medical product expertise to work for customers and partners, helping them to move quickly and confidently to market with safe and effective products. From concept through design, development and regulatory approval, ECHOBIO LLC can help you create better products.

EchoNous creates transformative handheld point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools providing more clinicians with increased information faster. Visit our website at https://www.echonous.com/ Explore a directory of our most popular content https://linktr.ee/echonous.kosmos

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit www.bostonscientific.com and connect with us on X, Instagram, and Facebook. At Boston Scientific, you will find purpose, a place to grow and opportunities to cultivate your passions. To search and apply for open positions, visit https://bostonscientific.eightfold.ai/careers. You may also review our social media guidelines at http://www.bostonscientific.com/social.

Eliem Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for neuronal excitability disorders with the goal of restoring balance in both the peripheral and central nervous systems to help patients live on their own terms. Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing life-changing novel therapies for disorders such as chronic pain, depression, epilepsy, focal onset seizures, and anxiety – conditions that make simple daily activities challenging for impacted patients.

Founded in 2002 and headquartered in Seattle, WA, EMulate Therapeutics is a clinical-stage therapeutic device company. EMulate Therapeutics has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE®) to specifically regulate signaling and metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called EMulate Therapeutics Voyager. The company's goal is to transform disease treatment on a global scale with ulRFE®. The proprietary technology has the potential to be applied to a wide range of conditions as well as veterinary medicine and non-medical applications. EMulate Therapeutics' initial focus is on the treatment of patients with brain cancer who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in oncology and pain treatment.

Evergreen Sciences, Inc. is a company that is dedicated to improving public health by developing and marketing accurate molecular and immunological testing systems. Theyoffer analytical testing for safety and quality of food matrices. Their focus is to detect and even quantify the foodborne and waterborne pathogens, monitor and determine nutritional analysis and harmful residues.

At Faraday Pharmaceuticals, Inc., our mission is to improve quality of life for patients after acute critical illness by minimizing damage to cardiac and skeletal muscle.

FenoLogicahelpsscientists gain insight into complex cellular interactions, creating a deeper understanding of human disease to improve patient outcomes. Our combined instrumentation and Cloud-based quantitative biology tools expedite the understanding of disease susceptibility and causation, leading to optimized therapeutic solutions.

Fluke Biomedical manufactures biomedical test and simulation products, including electrical safety testers, patient simulators & performance analyzer.

Fred Hutch is an independent, nonprofit organization that also serves as the cancer program for UW Medicine. Together we provide the specialized focus of a top-ranked cancer center and the comprehensive services of a leading integrated health system.

From the beginning Sonosite has been dedicated to empowering clinicians to continue innovating the practice of medicine for the sake of providing better patient care. They continue to partner with clinicians to bring the benefits of ultrasound to the point-of-care.

Fungi Perfecti® - makers of Host Defense® Mushrooms™ - is a family-owned company specializing in mushroom mycelium-based supplements. Founded by Paul Stamets in 1980 with the goal of building a bridge between people and fungi, Fungi Perfecti® has become synonymous with cutting-edge mycological research and innovative mycological solutions. Under Paul’s visionary leadership, we have made significant breakthroughs revealing the power and potential of mushroom mycelium. This is the foundation of the Host Defense® brand. Based near the Olympic Rainforest in Washington state, we are one of the best-documented and longest-standing mushroom supplement companies in the USA. Since its inception, Fungi Perfecti® has been the industry leader in research on the endless potential for the use of fungi in everything from water filtration (mycofiltration) and ecological rehabilitation (mycoremediation), to using beneficial mushrooms in the form of supplements to support human health. Our continued mission is to explore, study, preserve, and spread knowledge about the use of fungi for helping people and planet.* *These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Genemod helps scientists maximize productivity in their research to drive the next generation of medicines. Genemod helps solve problems of data sharing and data archiving for research labs by providing inventory, experiment management, applications, and data, all in one collaborative workspace.

The Geneva Foundation is a 501(c)3 nonprofit established in 1993 with the purpose to ensure optimal health for service members and the communities they serve. This purpose is accomplished through our mission to advance military medicine through research, development, and education. Geneva has 30 years of experience in delivering full spectrum scientific, technical, and program management expertise in the areas of federal grants, federal contracts, industry sponsored clinical trials, and educational services.

Georgetown University is a Higher Education institution that offers a variety of academic programs and services.

Gestalt transforms pathology through an intelligent, configurable, and vendor-neutral, AI-driven, digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. This platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing their invaluable experience where it matters most. *Research Use Only (RUO) unless following CAP guidelines for LDT.

GMJ Technologies, Inc. develops novel analytical technologies for efficient analytical workflows in biotherapeutic development and omics technologies

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

Multivalent RNAi Platform, Delivery

HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases with next-generation approaches designed to enable the body’s immune system to prevent and cure disease. We have engineered our technologies to Access, Activate, and Amplify the immune system’s natural ability to create antibodies and T-cells that fight cancer and infectious diseases such as SARS-CoV-2. We are developing multiple product candidates from our proprietary discovery platforms, including LION™, which has the potential to provide health benefits to a broad patient population. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. HDT Bio offers a comprehensive compensation plan which includes health insurance for employees and dependents (inclusive of multiple plants to choose from, including a $0 premium plan with HSA and company contribution), generous PTO (11 observed holidays and week long year-end closure), stock options with Carta Tax Advisory for equity and tax support, flexible spending accounts (FSAs), commuting benefits (ORCA or paid parking), and retirement benefits with company match. HDT Bio Corp. is an equal opportunity employer committed to a diverse and inclusive workforce. This environment is encouraged by HDT's culture, which supports women in science through our Women+ group, creates inclusive events to highlight the diverse cultures represented by our staff, and with the adoption of an open office environment for all.

Healionics is addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure. Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of occlusion and infection suffered by current devices. We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices: scarring and infection. The company is currently conducting human studies of STARgraft and has 36 patents issued or pending.

Helix BioMedix develops bioactive peptides based on specific natural cellular sequences for targeted topical efficacy. Our extensive library of proprietary peptide sequences can be used to treat a growing range of dermatological conditions including acne, rosacea, fungus and MRSA. Our mission is to enrich clinical practice and patient/consumer well being by developing topically-applied products which offer the health, beauty and safety benefits of our advanced bioactive small molecule peptide technology.

Histone Therapeutics is a biotechnology company at the forefront of precision epigenetic reprogramming that is focused on enhancing cell function and treating disease by controlling gene regulation. Our team shares the conviction that new drug modalities based on protein modifiers of chromatin remodeling could provide new options for treating disease and enhancing the human condition.

Ice Bear Therapeutics SPC is a social purpose company based in Seattle, WA, founded 2021, with the mission of bringing affordable insulin to patients with type 1 or type 2 diabetes.

IEH is an international lab & consulting services company, offering a comprehensive portfolio of lab testing services and consultation across multiple industries. IEH works with food production plants and manufacturers to ensure that the products released into our global supply are tested, safe, and in compliance with regulatory standards. Since 2001, IEH has expanded it's reach to service over 10 countries, with more than 100 locations covering the United States, Canada, Mexico, Germany, England, Austria, Poland, Netherlands, China, and Australia. Our lab services include but are not limited to food microbiology, analytical chemistry, allergen testing, GMO testing, authenticity testing, claim and forensic analysis, molecular epidemiology, and FDA detention. Our consulting team provides innovative and proven food safety solutions by designing and implementing testing programs to reduce risks associated with food production, and provides crisis management and regulatory support to our food partners.

While biopharma research is complex, biosourcing shouldn't be. We provide human immune cells, along with custom development and consulting services. Our scientists have decades of experience solving complex biomaterial and product development challenges for leading biopharma companies, CROs, and academic research institutions.

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson’s disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

InduPro is a biotechnology company that brings proteins on the cell surface closer together, manipulating their interactions and opening new possibilities for treating various conditions.

IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention/detection, drug discovery and development, clinical disease management, and precision health equity.

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm's lead program is focused on the highly validated, genetically-defined target, HSD17B13. There is extensive, consistent evidence that genetic variants in expression of HSD17B13 are associated with significantly lower rates and severity of multiple liver diseases. Building on these novel insights into the biologic activity of HSD17B13, Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein.

Inmedixfocuses on autonomic nervous system (ANS) control of stress responses within the brain. In the setting of an autoimmune disease, ANS stress can significantly intensify an autoimmune disease. Inmedixcall’sit Immuno-autonomics. Theyseek to understand and block this process to allow current autoimmune disease therapies to work much better.

The Institute for Disease Modeling (IDM) is part of the Bill & Melinda Gates Foundation's Global Health Division. IDM's goal is to support global efforts to eradicate infectious diseases and achieve permanent improvements in health by developing, using, and sharing computational modeling tools and promoting quantitative decision-making. Improving the health of all people, especially those in the most vulnerable populations, is a pressing and complex problem that engages diverse contributors, from health workers on the ground to funding agencies that provide resources and support. Data-driven approaches, including the development of dynamic models, statistical analysis, and the development and application of innovative algorithms, make fundamental contributions that inform primary research programs, intervention strategies, resource allocation, and other avenues of health care delivery.

Intrinsic Medicine is a preclinical-stage therapeutics company leveraging human-identical molecules as new medicines. Their initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells as well as the gut microbiome

By developing novel and affordable vaccines for all populations worldwide we're addressing health inequalities and empowering people to live healthy lives Inventprise is a mission driven vaccine manufacturing company developing vaccines that have shown a more robust and broader spectrum of protection than currently marketed conjugated vaccines. Our lead vaccine candidate is a 25-valent pneumococcal conjugate vaccine (PCV) funded by the Bill and Melinda Gates Foundation (>$100M) and aimed at large-scale supply to Low-Middle Income Countries. Additionally, we have a robust pipeline of vaccines and vaccine technologies, that have both viral and bacterial applications. Inventprise was founded in 2012, and is led by founder and Executive Chairman, Subhash Kapre PhD, former SVP and Corporate Officer of Serum Institute of India and Chief Executive Officer, Yves Leurquin, former general manager of Takeda Vaccines, Europe. Inventprise is based in Redmond, Washington, we have over 100,000 square feet of recently built, state-of-the-art facilities that have the capacity for large scale volume (>150M annual doses). With over 100 employees mostly exceptionally qualified industry scientists, and manufacturing professionals, Inventprise has created a large and dynamic presence in the Washington State Life Sciences environment.

Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners.

Kent Laboratories is a biotech manufacturer located in Bellingham, WA. They specialize in in vitro diagnostics and the production of polyclonal antibodies.

At Kestra, we stand for patients at-risk and the people who care for them. Together we work to protect, support, and empower them with wearable technologies, tools, and better answers as they navigate life's most challenging medical events. Cardiovascular disease is the number one cause of death globally. We're taking a fresh approach to cardiac monitoring and delivery of definitive therapy with wearable products and applications. We aim to make the entire recovery process easier for patients by bringing comfort and assurance to them—along with advanced clinical insights and tools to their medical care teams. Kestra is a privately held, Bain Capital portfolio company, headquartered in Kirkland, Washington USA. Visit us at www.kestramedical.com

Kinea Bio is a patient-focused biotechnology company striving to accelerate the development of next-generation AAV-based gene therapies to treat various diseases. The company is located in Seattle, Washington and is dedicated to developing innovations to fight genetic diseases.

Kineta is a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives.

KitoTech Medical is a Seattle-based medical device company that has developed microMend PRO, a unique wound closure device. microMend PRO is a new wound closure device that is as effective as sutures and as fast and easy to apply as a bandage. It delivers superior clinical results and improved patient experience while reducing procedure costs. microMend PRO can close wounds up to 50 cm in length and is effective in closing all types of lacerations including those with jagged edges. Our products are used by medical personnel in emergency medicine, dermatology, surgeons, and more. Request a quote for your clinic today!

Know Labs is transforming non-invasive medical diagnostics. The proprietary technology platform uses radiofrequency (RF) dielectric spectroscopy and can be integrated into a variety of wearable, mobile, or bench-top form factors. The first application is a non-invasive continuous blood glucose monitoring device that will provide the user with real-time information on their blood glucose levels, assisting billions of people with diabetes and prediabetes to manage this medical condition. Know Labs is a public company whose shares trade under the stock symbol KNW (NYSE American).

Koidra is an intelligent automation company, dedicated to modernizing the automation of manufacturing facilities, with the high-tech greenhouse industry being the core market. Our tiered products deliver a comprehensive solution that enhances industrial efficiency.

Komo Biosciences is a revolutionary gene editing startup that has emerged with breakthrough integrase technology from the University of Hawaii. The company has launched from stealth upon publication of groundbreaking precision genome engineering discovery.

Küleon is a drug discovery company leveraging proprietary, AI-based technology to identify novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders. We’ve created a proprietary portfolio of serotonin receptor ligands designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved agonism characteristics such as low-to-no hallucinogenic or cardiotoxic liability, as well as modified PK/PD profiles when compared to other known atypical antipsychotics and serotonergic drugs. Serotonergic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists were not designed with an eye towards functional selectivity. Our novel compounds are designed for functional selectivity via biased signalling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects. Our proprietary molecular scaffolds and compounds are novel and patentable, providing us with a tremendous strategic foothold in the market as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders. We are collaborating with some of the world’s leading academic researchers and key opinion leaders in the serotonergic and atypical antipsychotic drug development space. Please reach out if you would like learn more about the work we are doing with our collaborators!

LabConnect improves lives by partnering with pharma/biotech companies and clinical research organizations (CROs) to accelerate the development of new medicines around the world. An independent, global, one-stop-shop focused on delivering central laboratory services that are tailor-made, timely, and flexible, LabConnect provides unparalleled program oversight and support to meet the evolving study demands from traditional to increasingly complex trials. With deep and unmatched experience, LabConnect's team of scientific experts serves as an extension of our client's clinical teams, quickly coordinating all laboratory-related needs and providing end-to-end analytical and logistical solutions. Offering a full suite of services from real-time sample tracking and data integration to groundbreaking scientific support services, LabConnect is the global partner of choice for central laboratory services. For more information, visit www.labconnect.com

Link selects validated cancer targets and novel target combinations to build on existing knowledge in creating better molecules. Our strength as a leadership team comes from decades of previous experience and collaboration in both academic and industry environments. At Link, we know that our goal is elusive and that the work we do is not easy, but we are focused and determined to create better therapeutics. We are not alone. Our mission is supported by an outstanding Board of Directors and collaboration with industry-leading partners.

Loftus Labs provides data analytics, engineering, and data science to companies with a primary focus on Agribusiness. Born out of a 100-year farming tradition at Loftus Ranches and decades of combined experience in analytics, we develop the solutions and services agriculture companies need in data analytics, engineering, and modeling. We work with companies of all sizes, and at any stage of the data journey. Whether it's building a data warehouse, creating dashboards and reports, or developing advanced models, we can help you with your toughest data issues.

In 2022, we became part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services. Learn more at absolutebiotech.com. The extensive LSBio reagent catalog contains over 750,000 products, including 500,000 monoclonal and polyclonal antibodies, 50,000 immunoassays and kits, recombinant proteins, biochemicals, and cell lysates that it sells directly and through a network of international distributors. With over 20 years of expertise in antibody production, validation and immunohistochemistry (IHC), LSBio is a world leader in the antibody industry. LSBio is committed to offering unparalleled customer service and the highest quality reagents to assist our customers in accelerating their research.

Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases.

For organizations committed to providing the best behavioral health, human services, or wellness care, Lyssn's AI is the modern evidence-based quality improvement and training solution that provides visibility into human interactions and integrates expert-developed best practices so organizations can measure, train, and improve evidence-based practice at scale while meeting regulatory requirements. And, Lyssn requires dramatically less labor than current approaches with superior results at lower cost.

Magnolia Medical Technologies is on a Mission to ZERO®. Today, we offer healthcare institutions a solution to some of their biggest hidden problems – contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike. We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which we’ve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis. Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio – consisting of over 100 issued method, apparatus, and design patents and 70+ patent applications pending – to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.

MalarVx is a bio-pharmaceutical company located in theCenter for Infectious Disease Researchfacility in Seattle, Washington.MalarVxwas founded to address the myriad challenges of creating a safe, affordable, effective malaria vaccine using innovative new technologies discovered through research.They are focused on the development of in vitro culture systems for the malaria parasite which will lead to the development of an effective whole-parasite vaccine. Theycollaborate with researchers in non-profit institutions, university infectious disease programs, foundations committed to solving diseases of the third world, and for-profit pharmaceutical and medical devices companies.

Marqmetrixdelivers innovative products that allows customers to use Raman Spectroscopy (optical measurement) to analyze and deliver an exact level of product quality with minimal interruption to the business process

Matchstick’s premier product, PIXUL (forPIXelatedULtrasound), is a tool that processes each and every well of a 96-well microplate consistently and quickly.

The goal of Medchem Source is to provide high quality, cost effective research products and innovative services to customers who range from multinational fully integrated pharmaceutical companies to development stage biotechnology companies.The main facility in Federal Way is capable of handling complex organic synthesis which includes the synthesis of building blocks derived from various classes of heterocyclic compounds, natural products, peptides, natural and unnatural (synthetic) amino acid derivatives.

Fecal microbiota transplant (FMT) has been gaining traction among healthcare providers, researchers, and patients, with hundreds of clinical trials underway and compelling data on FMT benefits for a variety of medical conditions, far beyond its initial application for Clostridium difficile. However, existing FMT treatment methods are time consuming, costly, and sometimes invasive. The team at MicrobiomX recognized the opportunity to develop a scalable, safe, rapid FMT solution.

Reliable. Accurate. Approachable. We are a food testing laboratory that provides accurate, timely, and cost effective results to small and large corporations alike. Our goal is to make your job easier by delivering consistently reliable results that you can depend on. Find out how we can help you.

Microsoft is a technology company that offers a wide range of software, cloud computing services, hardware, and artificial intelligence solutions.

Molecular Testing Labs is a mission-driven, innovative health sciences company specializing in precision laboratory diagnostics. Molecular is committed to revolutionizing accessibility to testing via proprietary technology systems, advanced logistics, and cutting-edge research and development. We are pioneering and innovating distinctive distribution and specimen collection methods that open access to medical testing where geographic, financial, and stigma barriers once created gaps in the healthcare industry. We provide accessible and innovative laboratory solutions through collaborative partnerships with payors, private healthcare institutions, universities, commercial partners, and public health organizations. Molecular Testing Labs is a CLIA-certified and CAP-accredited, state-of-the-art, esoteric and reference laboratory. We specialize in high-complexity, molecular testing with an extensive portfolio of services including infectious disease, toxicology, targeted sequencing, single nucleotide polymorphism (SNP) genotyping, and Next-Generation Sequencing (NGS), and high-resolution immune profiling. Molecular Testing Labs offers a variety of clinical trial services comprising of assay development, trial site training, investigator support, and customized reporting. We apply the maximum level of control to obtain the most consistent and highest quality results. Molecular Testing Labs is founded on three guiding principles – Compliance, Innovation and Partnership. For more information, please visit our corporate website – www.moleculartestinglabs.com.

Monod Bio is a Seattle-based biotechnology startup and a spinout from the David Baker Lab at the University of Washington's Institute for Protein Design. The company uses AI-powered de novo protein design to create novel protein binders and biosensors for in vitro diagnostics (IVD) and research use only (RUO) applications. Monod Bio's proprietary platform enables the creation of computationally designed proteins, including its NovoBodies™, to address unmet needs in the IVD and RUO biotechnology industries.

Mountain Shadow Nursery is a plant tissue culture lab and wholesale nursery that specializes in custom propagation and tissue culture production of choice plants.

Mozart is developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway.

Myosana Therapeutics, Inc. is leading the efforts in developing new gene therapies that will slow skeletal muscle degeneration and heart failure.

A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q² Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

Novuson, a spinout from the University of Washington's highly regarded Applied Physics Laboratory's Center for Industrial and Medical Ultrasound, is developing its Direct Therapeutic Ultrasound (DTU) technology platform for coagulation and hemostatic control in surgical and trauma procedures.

Welcome to the Oasis Diagnostics® LinkedIn Company Page! We're so glad you found us. Oasis Diagnostics® Corporation was founded in 2002 to address a growing need for non-invasive saliva based technology for rapid testing, sample collection, and molecular diagnostics [DNA, RNA and proteins] in the Life Sciences area. The Company is dedicated to meeting the need for more effective screening tools, which may be applied to the early detection of diseases and medical disorders, utilizing non-invasive test specimens, particularly oral fluids (saliva). The Company’s range of collection and [future] diagnostic tools are covered by a portfolio of issued US, EU and International patents. Recognizing that early diagnosis is the key to disease prevention on a global basis, the Company directs its research efforts towards the development of oral based rapid, point-of-care, laboratory-based and molecular products, which fit into a Corporate objective of improving the quality of healthcare for our global customers.

Oisin Biotechnologies is a longevity therapeutics platform company focused on creating genetic medicines to combat a variety of age related diseases. When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases. Oisín Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.

Olympic Protein Technologies is a contract research organization focused on providing high quality protein science services for clients and partners. The quality of proteins are vital to the success of experiments that form the foundation of the discovery and development of therapeutics. Our staff has a wealth of collective experience in top-tier biotechnology companies successfully designing, producing and characterizing protein therapeutic candidates as well as critically important antigens and reagents. This experience includes solving problems associated with the expression/purification of challenging proteins. The aim of our team is to leverage this knowledge to provide the best experience and outcomes for our partners and clients by providing quality science delivered with full engagement and the highest standards, integrity, and data security. We currently offer construct design, expression, protein production & characterization, biomolecular interaction analysis, antibody generation, and protein engineering services. We also can leverage our network of protein science contacts to provide access to other types of analyses, such as advanced biophysical technologies, for your project. As we grow we will build on our existing capabilities while broadening our offerings to include other protein science services. We are located in Seattle Washington USA.

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology.OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.

OncoSenX is a developer of transient gene therapies designed for solid tumors. The company is headquartered in Seattle, Washington and is focused on developing tumor-killing therapeutics using genetic information.

Oncotherapy Solutions LLC currently has three preclinical programs and a lead drug conjugate for ovarian cancer and triple-negative breast cancer. The lead drug conjugate is also expected to be effective on cancers of the colon, pancreas, lung and brain. The second research program is on the development of new multi-kinase inhibitors for the treatment of a variety of hematological and solid tumors. This program is in early proof of concept preclinical phase. The third research program is on the development of novel vaccines and checkpoint inhibitors to activate the patient's own immune cells to recognize and destroy cancer cells. This program is on hold until appropriate funds are secured.

At Opticyte, we are committed to transforming the standard of care for the leading causes of organ failure, including sepsis. The problem is massive, is expensive to treat, and leads to one death every 2.8 seconds globally. Current technologies fail to provide clinicians with the definitive data they need to diagnose, monitor, and treat patients in real-time, when they have the best chance of preventing organ failure. Unlike existing oximeters, our VitalO₂ is accurate for people of all skin tones. Our VitalO₂ monitor is the first and only single solution to provide definitive, continuous, and actionable insights for these critical unmet needs. The FDA awarded Opticyte Breakthrough Device Designation on the strength of our clinical data and the promise of our technology to save lives. Opticyte's executive and advisory team includes pioneers in new optical spectroscopy and multivariate analysis technology, leaders in medical device commercialization, and medical clinicians. The company's early funding successes, research validation, and product development milestones provide credibility and reinforce our position as a disruptive medical device innovator.

Ora Biomedical, Inc. is a new pharmaceutical company in the longevity biotechnology sector that identifies and characterizes healthy aging therapeutics for further clinical and commercial development. Ora Biomedical separates itself from other longevity biotech companies by building in large-scale drug discovery and validation at the core of our scientific operations. With robust preclinical discovery at the heart of our approach, we identify novel aging targets and new interventions for known targets. Most importantly, we will leverage large-scale operations to perform drug studies that combine known and novel healthy aging interventions to identify those that produce breakthrough increases in healthy lifespan and/or mitigate disease-mediated pathology.

The future of preclinical drug discovery is engineered tissue. The founders of OrganOmics have developed cutting-edge, live human brain tissue models derived from stem cells. They have partnered with the neurosurgeons to source patient-derived cancer tissue to induce a realistic cancer pathology. Their patented microfluidic platform automates the assay, detailing drug responses of thousands of tissues generating high-content data. This vast, cellular response data is processed through artificial intelligence to predict the clinical outcomes of each candidate drug.

Working to develop drugs that reducing or eliminatehearing loss due to aminoglycoside therapy.

A device from OtoNexus Medical Technologies uses air-coupled ultrasound technology to accurately assess middle ear infections, and in particular to differentiate when and when not to prescribe antibiotics.

Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.

Developing a single cell immunoprofiling platform.The company’s tools quantify and assess what types of cells are in samples based on the composition of surface proteins.

On a global scale, shellfish aquaculture provides a sustainable, low input source of healthy food. When practiced sustainably, shellfish farming can enhance water quality while providing habitat and other ecosystem services in the marine environment. Pacific Hybreed is the first commercial shellfish breeding company in the U.S. Our products offer both resilience, to mitigate the impact of threats to current production, and growth, through enhanced yield for producing Pacific oysters, Manila clams, Kumamoto oysters, and rock scallops, among other commercially important shellfish. Based on decades of university-based research by founders Dennis Hedgecock and Joth Davis, our technology responds to a changing global climate, warmer and more acidic oceans, and emerging diseases, including Pacific Oyster Mortality Syndrome (POMS), a viral disease that has devastated oyster production worldwide. Specifically, hybrid vigor, resulting from our crossbreeding program based on world class quantitative genomics, can enhance yield and resilience in shellfish, as it has in corn and other crops, without relying on genes from unrelated species (i.e., no GMOs). Our products will not interbreed with wild stocks.

Pacific Northwest National Laboratory advances the frontiers of knowledge, taking on some of the world’s greatest science and technology challenges. PNNL is a U.S. Department of Energy national lab with distinctive strengths in chemistry, Earth sciences, biology, and data science that are central to our scientific discovery mission. PNNL’s research lays a foundation for innovations that advance sustainable energy through decarbonization and energy storage and enhance national security through nuclear materials and threat analyses. PNNL collaborates with academia in its fundamental research and with industry to transition technologies to market.

PAI Life Sciences is a biotechnology company located in Seattle, WA, specialized in the developmental and translational research necessary to bring products from the laboratory to bedside. Its mission is to address neglected diseases throughout the world with the idea of “serving the underserved.” The company has developed novel protein biotherapeutics and has a pipeline of products ranging from infectious disease vaccines and adjuvants to therapeutics for cancer.

PATH is a global team of innovators working to accelerate health equity so all people and communities can thrive.

Pattern Computer, Inc., a Seattle-area AI & ML company, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems. As the Company applies its computational platform to the challenging fields of drug discovery and diagnostics, it is also making major pattern discoveries for partners in other sectors, including biotech, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance. Highlights: • Innovative / Proprietary Technology • Pattern Discovery Engine™ discovers and generates valuable hypotheses and insights into complex data, revealing novel patterns that cannot be discovered using conventional techniques or tools • Pattern produces exceptionally valuable assets within some of the most fiercely competitive domains … and commercializes them • Multiple high-growth markets: immediate focus most daunting yet immediate promise for life-changing & life-saving contributions to society including: • Life Sciences • XAI • Commercial Journey along with us as we move from creating our high-value assets to capitalization/commercialization of them- taking AI by storm with our focus on Third Wave AI.

Staffed by expertly trained geneticists, veterinarians, and technicians, the lab at Paw Print Genetics is equipped with the latest technology for the testing and analysis of canine genetic diseases. Once your tests are completed, you receive a clinical report with results, interpretations and recommendations, in addition to a Canine Genetic Health Certificate™. The staff also provide genetic counseling and consultations.

PharmaIN Corporation is a company dedicated to developing proprietary peptide drugs for in-home treatment of liver disease and cancer. PHIN-214 is an investigational drug therapy that has not been approved by the FDA or any other regulatory agency.

Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software. Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.

Phenome Health is a research organization dedicated to preventing disease and taking the guesswork out of healthcare. We are driving a revolution by moving past the disease-focused “find it and fix it” era to wellness and prevention that enables all of us to live longer and healthier lives.

A specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:

Photon Biosciences' core technology is a new ultrasensitive detection platform that combines bioengineered proteins with a uniquein vivobiomineralization process that results in a number of different genetically expressible luminescent bionanoparticles that are non-bleaching and non-blinking with luminescence intensities that rivals and surpasses many fluorescent organic molecules. The excitation and emission wavelengths of these expressible bionanoparticles can be tuned with the composition of the mineralization process and span much of the visible and near infrared regions of the electromagnetic spectrum. Because of its unique photophysical properties, PBS® has been developed into new ultrasensitive probes for biomolecular research, detection technologies, and cellular imaging.The company is developing a test to detect contamination in donated platelets.

pH Sciences develops safe, innovative ingredients; manufactures those ingredients to exacting scientific and regulatory standards; and supplies those ingredients to dietary supplement and medical food companies who market finished products that are highly differentiated and effective.

Cell models for human disease.

Pluristyx is a pioneering company at the forefront of stem cell technologies. With a mission to revolutionize the field of regenerative medicine, Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies. The company's proprietary platform, panCELLa, represents a transformative leap in stem cell research, offering enhanced freedom to operate and unparalleled potential for medical advancements at a significantly accelerated timeline. Operating from two cutting-edge North American sites, Pluristyx is dedicated to driving progress and innovation in the realm of stem cell therapies. In July of 2023 Pluristyx and panCELLa merged. Pluristyx offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.

Precision Image Analysis (PIA) is an innovative, cloud-based image post-processing service delivering analysis, reports and expertise at lower cost with improved consistency through standardization and greater efficiencies in workflow. "The cost and value of PIA services is consistently better than that of purchasing and maintaining specialized software especially when considering the need to train staff to effectively and efficiently interact with that software."​ ~ Dr Michael Wheat Attending Physician, Cardiologist Porter Hospital PIA offers CT and MRI post-processing services to the healthcare and research communities with specific expertise in Cardiac, Vascular and Neuro. Advanced medical imaging often needs time-consuming post-processing by experienced experts. This requires costly software, hardware and extensive training for personnel. PIA provides advanced medical imaging post-processing as a service. Why Outsource Image Post-Processing? --Immediate Access to Advanced Imaging Analysis, Reports & Experts -- PIA specializes in CT & MRI post-processing with specific expertise in Cardiac, Vascular and Neuro post processing. --No Capital Costs - Hospitals and diagnostic imaging centers are under continued pressure to bring down capital expenditures. --No Hardware, Maintenance or Upgrade Costs - High value post-processing WITHOUT costly ongoing fees & overhead also associated with employee retention, training and certification. --It's a service - PIA provides image post-processing as a service to hospitals, diagnostic imaging centers and researchers with no training required. --We never go on vacation. When planning for your medical image post-processing needs, think of PIA as your outsourced expert. Let us show you how we can improve your WORKFLOW and CASHFLOW. Visit www.piamedical.com or contact us at (425) 822-8199 | info@piamedical.com.

Precision Mechanical is a full service contractor specializing in biomedical and laboratory equipment service and repair.

Designs and implements preclinical and CMC programs for virtual biotech to mid-sized pharmaceutical companies.

Prevencio is Revolutionizing Blood Tests For Cardiovascular Disease || Powered by Artificial Intelligence (AI) || Preventative Medicine for Heart Health Prevencio's purpose is to prevent the preventable. 80% of cardiovascular disease, including heart disease and stroke, are preventable (CDC). Prevencio's personalized blood tests provide earlier detection and prevention which can diminish unnecessary procedures and related side effects, as well as improve patient outcomes. Published in top-tier cardiology journals and presented at leading cardiovascular meetings, Prevencio's patented, proprietary technology has been used to create seven life-saving cardiovascular tests, with more in development.   Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. To learn more visit us at: www.prevenciomed.com

We realize product visions that enhance people's lives. Product Creation Studio is an integrated product development consultancy. We fuse our passion and expertise in strategic design and precision engineering to create, innovate, and solve complex challenges for our clients across the consumer, medical, and industrial fields. From burgeoning start-ups to top-tiered companies, we make products happen.

Proniras Corporation is a clinical-stage biotechnology developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system disorders. The Company’s lead program PRN-001-01 (tezampanel) is being clinical developed as a treatment option for opioid withdrawal and related disorders of addiction. Although effective treatments exist for opioid addiction, painful and difficult withdrawal is one of the primary reasons why current treatment fails, and relapse occurs. By alleviating the symptoms associated with opioid withdrawal, Proniras hopes to help patients successfully discontinue opioid usage and sustain an opioid-free life. Proniras was formed in 2017 by Accelerator Life Science Partners.

Proteios Technology is a spin-out from the University of Washington developing a flexible protein technology platform. Proteios’ protein technology is based on a patented dodecapeptide (affinity tag) that exhibits micromolar affinity for silica substrates and eluded using low-cost, biologically-safe reagents. When incorporated to either the N- or C-terminus of a protein, the tag provides a convenient handle for automated protein manipulations, including protein/biopharmaceutical purification, cell enrichment/depletion for cellular therapies, microtiter-based high-throughput (parallel) protein purification, printing protein or antibody chips for HTS, immobilized biocatalysis, and biosensors. Proteios is initially focused on providing easy-to-use, affordable and rapid kits to purify recombinant proteins, where we have a competitive advantage in cost (5x-10x less expensive), throughput (12x improvement), quality (50% improvement in failure rate), purity (> 90%), yield (> 15 mg), and safety (absence of heavy-metal impurities by using biologically-safe reagents).

Viva BioInnovator (VBI) is the specialized investment and incubation division of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program. VBI's unique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1"​ transformation. This spark launched our "equity for service (EFS)"​ investment and incubation model. VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy. If you would like to learn more about us, please visit: www.vivabioinnovator.com Or send an email to innovation@vivabiotech.com If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com

RAIN is a nonprofit BioTech ­incubator in downtown Tacoma, WA. RAIN Incubator's mission is to attract, train and retain biotech companies in Pierce County. RAIN will be successful if, in the next 10 years, Pierce County is a thriving hub of biotechnology talent, small businesses, and educational opportunities aimed at serving a diverse and growing group of scientists and business owners.

Leaders across Research, Translational Medicine and the Clinic rely on RareCyte as a one-stop resource for Spatial Biology and Liquid Biopsy solutions. Headquartered in Seattle, WA, RareCyte is an innovative precision biology company that has developed technologies and end-to-end integrated platforms enabling advances in oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. Our highly multiplexed fluorescent imaging systems, reagents and contract services empower investigators to unlock spatial context for key biomarkers and develop therapeutics and companion diagnostics through rare cell analysis.

Small Nugget. Big Difference. We at Rebellyous (Formerly Seattle Food Tech) are on mission to make the perfect chicken nugget. We started by taking out the actual chicken and using protein-rich plant ingredients. Now, we're developing a whole new manufacturing system that is cleaner, more efficient, and better for the people who operate it. Today, we make crispy and juicy plant-based nuggets, tenders and patties. Our heat-and-serve options are available in retail, foodservice and school cafeterias all over the US. Together, we're changing the food system - one little nugget at a time.

Remmie Health is a digital health technology venture that delivers next-generation, AI-enabled, ear-nose-throat care for easier, accessible diagnosis, timely intervention, and exceptional patient care. Remmie is a patient-centric, primary care telemedicine/at-home examination device + API + AI system that enables patients/consumers to receive virtual/hybrid care from healthcare professionals, covering 22+ most commonly occurring respiratory conditions, causing over 120 million annual visits as the leading reason for ambulatory care, impacting every family 2-9 times a year. The winner of the Muse Innovation Fellowship, UCLA Knapp Venture Competition, and Rice Business Plan Competition, Remmie Health is a UnitedHealthcare Accelerator (powered by Techstars) and Plug and Play portfolio company. The company is based in Seattle, WA.

Resolution Bioscience, a part of Agilent, is pioneering next generation cancer diagnostics that enable physicians to tailor treatments for each patient using only a blood test — a liquid biopsy. Our proprietary molecular analytics platform interrogates cell-free DNA for actionable information that, until now, has only been accessible through invasive biopsy procedures. We have developed over 50 focused panels and are currently working on companion diagnostics to support therapeutic approvals. We are dedicated to improving cancer outcomes through a suite of clinical tests to guide selection of targeted therapies and monitor their effectiveness over time.

Revalesio is a clinical-stage pharmaceutical company committed to creating treatments for neurological diseases and conditions that lack adequate therapeutic options. Our therapies address cellular imbalances related to mitochondrial dysfunction and thereby modulate the immune response. They have been shown to protect neurons in models of chronic neurological diseases and improve recovery in acute neurological injury. We are partnering with internationally renowned scientists in biomedical research in a concerted effort to improve the lives of millions.

Cancer Drug Delivery Technology - enhances drug delivery with small molecule affinity-tethering compounds

RTI International is an independent, nonprofit research institute dedicated to improving the human condition. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development. We believe in the promise of science, and we are inspired every day to deliver on that promise for the good of people, communities, and businesses around the world. For job openings and career information, visit www.rti.org/careers. RTI reserves the right to remove any inappropriate or unauthorized content posted or contributed to its LinkedIn page.

Established by a dynamic trio of female entrepreneurs, S2Media stands as your premier partner specializing in the manufacture of prepared culture media, transport media, buffers, diluents, and solutions commonly utilized in microbiology laboratories. Born from a collective frustration with the status quo of customer service within the industry, S2Media swiftly emerged in Spokane, Washington, as the counterculture in the industry by providing an experience exponentially better! Apparent in both Product Quality and Customer Service… How you want it. When you need it. At S2Media, exceptional product quality and customer service aren’t just a tagline - they are the cornerstone of our business. We pride ourselves on delivering unparalleled quality products and personalized customer service that sets a new standard in the industry. As a women-owned and operated STEM manufacturing company, S2M occupies a unique space in the industry. Approaching nearly a decade in business, S2Media's success speaks volumes about our resilience, determination, and endless commitment to excellence. The name “S2Media" embodies the steadfast spirit of its founders: Stephanie, Sommer, and Molly, whose extensive expertise spans over five decades across various critical domains, including microbiology, regulatory compliance, operations, equipment, manufacturing, validations, quality management systems, and supply chain logistics. Above all, it is their commitment to surpassing customer expectations that drives their decisions. Join us at S2Media and experience what Exponentially Better means! Product Quality and Customer Service… How you want it. When you need it.

Sage Bionetworks is a trusted nonprofit leader in data sharing and reuse, enabling a rapid acceleration in biomedical discoveries and the transformation of medicine. Our mission is to drive a new age of discovery through truly open science and radical collaboration. Better Science Together.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Scisco Genetics Inc, a Seattle-based spin-off from the Fred Hutchinson Cancer Research Center, is a leading provider of sequencing services and products for genotyping the immune system.

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. On Dec. 14, 2023, Pfizer completed the acquisition of Seagen.

Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.

Seattle Cancer Care Alliance offers a bold and innovative approach in the prevention, treatment, and cure of cancer.Combining the talents, expertise, and resources of three world-renowned institutions—Fred Hutch, Seattle Children's, andUW Medicine—SCCAisable to offerpatients unprecedented survival rates.

Seattle Children's is a pediatric healthcare provider offering a wide range of healthcare services for children.

Selkirk Pharma, founded by industry experts in sterile fill/finish, delivers on its promise to be the most reliable manufacturer of injectable drug products, from compounding to product release. A new purpose-built, unidirectional facility in Spokane, WA features best-in-class equipment, including ultra-high-yield Bausch and Stroebel VarioSys filler with SKAN isolator technology for harmonized GMP compliance with US FDA and EU Annex 1 regulations. To support our rapid clinical trials materials program, ClinFAST™, a highly skilled and invested workforce offers in-house analytical and microbiology testing, regulatory support, and real-time QA review for on-time, in-full delivery regardless of volume. Vial Capacity Now Available!

Sesh is committed to improving care for cancer patients. The newest paradigm in healthcare is precision medicine, whereby each patient is given the right treatment at the right time. This strategy leads to the best outcome. In oncology, there are many different types of treatment - from chemo, radiation, and surgery to targeted inhibitors and immunotherapy. Sesh operates at the forefront of medicine, applying a precision oncology approach to the newest and most promising type of cancer therapy, immunotherapy.Our technology, RELOAD, allows each cancer patient and their oncology team to determine whether immunotherapy is the optimal type of treatment at a given time. For many patients, immunotherapy is indeed the best option, but other patients may be unlikely to benefit from immunotherapy due to biomarkers that prevent immunotherapy from being effective. RELOAD measures the presence of these biomarkers, so that informed treatment decisions can be made. Making treatment decisions utilizing the information from RELOAD can save a patient's life.

Shape Therapeutics is a biotechnology company that combines breakthroughs in AI, RNA technology, and synthetic biology to create safe, effective, and accessible medicines to help as many patients as possible. The company was founded with the mission to make programmable RNA medicines available for everyone. Shape Therapeutics is pioneering the field of programmable RNA Medicines.

Active Protection™ from Pathogens. Confidence to Live Well. Singletto's novel Oxafence® technology is being developed to meet the needs of healthcare, military, industry, and consumers - providing ongoing Active Protection from pathogens where it matters most.

Sironix Renewables is seed stage company developing a new line of plant-based surfactants for use in detergents, agricultural products, and oil recovery. The startup company is based out of the University of Minnesota and the Department of Energy Catalysis Center for Energy Innovation (CCEI) and has earned numerous Department of Energy and National Science Foundation grants for commercialization of it's technology.

SISCAPA technology is the smart shortcut to sensitive quantitation of protein biomarkers and targets. SISCAPA assays combine the precision of MRM mass spectrometry with the power of affinity enrichment to deliver a superior alternative to conventional immunoassays for protein quantitation. The SISCAPA workflow is highly automated and exploits familiar LC-MS/MS platforms widely used for drug and metabolite quantitation. At SAT we believe quantitation of proteins in biologic samples provides an actionable measure of the state of health, disease and treatment. We provide services and products for sequence-specific protein quantitation and robust generation of data in an automated, multiplexed and high throughput manner. Analysis is carried out using a generic workflow, allowing for validation and industrialization of processes for such applications as biomarker validation, protein bioanalysis, pathway research for therapeutic development and monitoring and for use in laboratory-developed tests. SISCAPA assays enable multiplexed quantitation of proteins over many orders of magnitude dynamic range. The generic, automated workflow ensures robust results with high throughput and precision. SISCAPA services include complete Assay Reagent Development or specialized Assay Implementation to maximize your up-time and help you quantitate proteins with unmatched precision. Our pipeline has generated reagents for SISCAPA quantitation of more than 250 different proteins to date, providing an unparalleled experience base.

Soiltest's quality laboratory has been serving the Northwest since 1976. We provide professional analytical testing for soil, water, plant tissue, feed and nematode samples. Our lab provides next-day results for feed, soil and plant tissue analysis. Quality results coupled with timely reporting make our services the best in the area. We focus on delivery options that are also convenient to the customer. We are able to deliver reports via: e-mail, fax and mail. Note, nematode identification sometimes takes 2-4 days to complete and water analyses can take up to 14 days to complete. Soiltest participates and excels in several proficiency testing programs. Soiltest is committed to providing accurate and precise results in all our analytical work. To assure this quality we participate in several sample exchange programs. Soiltest analyzes soil and plant samples quarterly under the North American Proficiency Testing Program. Quarterly manure samples are analyzed under the Minnesota Department of Agriculture Manure Testing Laboratory Certification program. DOE certification requires that the Soiltest laboratory pass quarterly water sample submissions. This means that the test results you receive are always as accurate and precise as humanly possible.

Solius has worked for almost a decade to isolatebeneficial UVBspectrumlight and package it into a safe, effective, smart device. They work with leading experts in the world of phototherapy and vitamin D research to develop and improve the product.

Sound Biologics creates innovative technology to better serve patients through the development of treatments for cancer. We aspire to discover and progress therapies that will impact human health and reduce the cost of biotherapeutics.

Sound Decision for Imaging's mission is to provide an objective and practical QC program to ultrasound department managers and service providers in order to:1. optimize clinical performance,2. reduce the cost of operations, and3. provide the technical elements needed for department accreditationby employing a new scientific approach to Ultrasound Quality Control.

SoundHealth is on a mission to help the world breathe free. As a startup, we specialize in AI-based, personalized, drug-free treatment designed to improve respiratory health. SoundHealth is founded by an experienced team of serial entrepreneurs in the technology and medical fields. SoundHealth's inaugural product, SONU, is the world's first FDA-authorized wearable device offering drug-free, spray-free, personalized relief from nasal congestion.

Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.

Clients call on Spannerwerks in situations when experience, expertise, and execution matter: when filing an IND, starting-up a study, or commercializing a new product. At these critical inflection points, workloads expand dramatically, and experts are needed. Clients are concerned about gaps in their teams and having someone to ensure nothing is missed. Spannerwerks is a consortium of experts covering all areas of drug and biologic development and commercialization. Our team fills in the gaps, partners with employees, and integrates the workstreams. We do the work so that you can focus on what is important and leverage your expertise to achieve your goals. While we are local to Seattle and willing to be on-site to work side by side with your employees,  we also have experience collaborating remotely.  This flexibility ensures that whatever your company structure, we will be able to become a part of your team. Spannerwerks is proud to be unique in pharma and biotech consulting in that we are woman-owned.

The mission of the company is to develop innovative diagnostic reagents, cellular therapeutics technologies and engineered cell products to help

Syntrix has pioneered the development of new therapies for over 10 years. As a clinical-stage company, we are tackling some of medicine’s most high-value diseases. One thing has remained unchanged however, our shared commitment to improving the lives of patients.

Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.

Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs

The company is developing a ventricular shunt, for children with hydrocephalus.

Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenient diagnostic tests to their patients. Tasso was originally founded to find a better way to collect blood instead of a painful fingerstick or time-consuming venous draw. Since then, our products have been used in pharmaceutical clinical trials, by Olympians as part of a new virtual anti-doping program, and broadly by hospital systems across the US.

Technical Safety Services is a leading compliance, calibration and certification service provider for laboratories, hospitals, and pharmacies with locations across the United States. Our customers include leading life sciences and healthcare companies and renowned research institutions. Our Family of Companies includes Technical Safety Services (TSS), Evergreen Medical Services, and Cornerstone Commissioning. We are rapidly growing and looking for additional passionate and talented employees to join our team and partner with TSS' customers who are doing dramatic work focused on improving the human condition.

TERN THERAPEUTICS is a privately-held biotechnology company founded in 2023 with a new vision for speeding the development of transformative, one-time gene therapy medicines for rare diseases. Guided by a team of leading physicians, scientists, and business leaders and in collaboration with patient communities, we are driven to deliver transformative treatments with urgency to those living around the world with rare disease.

We are proud to be the first Organic and Fair Trade certified bean-to-bar chocolate maker in North America. We’re dedicated to making our world a better place. And we’re finding ways to do it through our passion—bringing out the best of the cocoa bean. We are all connected. We touch one another’s lives in incredible ways. And we are responsible to and for one another. From the cacao farmer in the Congo, to the truck driver in Seattle, to the chocolate lover in Philadelphia—there is a thread that runs through us all. Theo believes in celebrating those connections, in strengthening them and in finding inspiration within them—inspiration to change the world. We know that every action has a result. That the choices we make here in Seattle, Washington touch lives across the planet in real and lasting ways. That knowledge, and that responsibility, is what drives us to do things differently, to help make the world a better place. We think about every choice we make, every action we take and how it will impact our interconnected world.

The Weinberg Group, a ProPharma Group company, is the global leader in regulatory and compliance services, with headquarters in Washington, D.C. For over 35 years, we have provided biotech, medical device, and pharmaceutical consulting services to companies of every size on every continent, supplying them with viable and efficient drug development pathways and compliance solutions. The Weinberg Group was acquired by ProPharma Group on January 25, 2019. By joining forces, we expand our current service portfolio of pre-approval/pre-clinical regulatory service solutions to also now include post-approval regulatory services, establishing an end-to-end global solution for our clients. Our service footprint now allows us to service clients at all stages of drug, device and biotechnology development, and in any geographic region.

TRIA’s core competencies encompass the discovery and research of immune-based therapeutics. Developing vaccines for influenza, nicotine, and more.

Truveta is a growing collective of health systems in the US with a mission of Saving Lives with Data. Truveta delivers the most complete, clean, and timely regulatory-grade EHR data for scientifically rigorous research. Truveta is trusted by leading life science, government, health system, academic and research organizations to accelerate adoption of new therapies, improve clinical trials, and enhance patient care.

TwinStrand Biosciences is a biotechnology company that specializes in ultra-sensitive genomic analysis using its proprietary Duplex Sequencing® technology. This innovative approach significantly reduces sequencing error rates, allowing for the detection of ultra-low-frequency genetic variants. This capability is essential for high-precision applications in cancer research, genetic toxicology, and monitoring cellular immunotherapies. Founded to enhance genomic accuracy, TwinStrand focuses on translating academic innovations into practical solutions for clinical and research environments. The company offers Duplex Sequencing Kits for various applications, including measurable residual disease detection in acute myeloid leukemia and mutation signature analysis. Additionally, it provides proprietary biochemistry and cloud-based informatics tools to identify variants that standard next-generation sequencing cannot detect. TwinStrand is also pursuing regulatory development to enhance decision-making in genetic toxicology. Through collaborations and partnerships, TwinStrand aims to expand the reach of its technology and improve global regulatory standards.

Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.

Uptake Medical® developed innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor®, was the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. Uptake Medical was acquired in July 2016 by Uptake Medical Technology Inc, a subsidiary of Broncus Holding Corp.

The United States Department of Agriculture is the United States federal executive department responsible for developing and executing U.S. federal government policy on farming, agriculture, and food. It aims to meet the needs of farmers and ranchers, promote agricultural trade and production, work to assure food safety, protect natural resources, foster rural communities and end hunger in the United States and abroad.

Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits. They’re using cutting-edge sequencing technology, statistical genetics, and machine learning to identify entirely new therapeutic targets.

Our purpose is to disrupt disease transmission. At Varro Life Sciences, we develop innovative products and technologies that make a global impact across economic and cultural borders. We are ambitious and dedicated in our pursuit to leverage technology that saves lives, ensures safe environments, and prevents future pandemics. The company was established in January 2020 as Y2X Life Sciences, and the company name was changed in October 2024.

Ventec Life Systems is a Washington-based medical device company that develops portable ventilation systems for patients with respiratory diseases.

Verda is bringing basic scientific expertise to product formulation and dosing to medical cannabis products.

Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. The company’s proprietary platform, powered by advanced machine learning, taps into uncharted chemical space to design de novo molecular structures with enhanced drug-like properties that range in size between small molecules and antibodies. Vilya is leveraging its platform to focus on previously difficult-to-drug therapeutic targets. Vilya was co-founded by a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners. The company has operations in Seattle and South San Francisco.

Virtici is an innovation and product development company. We work with a growing ecosystem of world-class scientists, universities, businesses, and investment groups. Together we increase our reach and capital, resulting in enhanced innovation, cost-efficient product development, and more valuable medical products for patients. Virtici is built on the foundation that life changing products are developed through innovation, hard work, and determination. Guided by our core values of innovation, integrity, dedication, teamwork and improvement, the Virtici team focuses on solving life’s biggest health challenges, creating and transforming scientific innovations into life changing medical products. We are always looking for extraordinary people with exceptional creativity and enthusiasm. Every employee contributes to shaping the future of the company. In our fast-paced and entrepreneurial environment, team members are expected to help solve big health-related problems.

Visus Therapeutics - With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.

VMRD was founded in 1981 by D. Scott Adams, DVM, PhD, and currently employs over 50 researchers, lab technicians and support personnel. From its site in Pullman, Washington VMRD develops and manufactures veterinary diagnostic test kits and related reagents for distribution in more than 77 countries. As a rapidly growing company, VMRD strives to preserve its family focused culture and core values of integrity and quality. VMRD's services division, performs specialized testing of raw materials, cells and seeds for the presence of adventitious agents to satisfy various regulatory requirements and quality assurance needs for the global serum, veterinary and pharmaceutical industries.

Washington State University is an academic institution that offers higher education and research services.

Wavely Diagnostics builds phone-based tools to support pediatric care. Their first tool is a phone app that can detect fluid in the middle ear to help a doctor diagnose and treat ear infections remotely.

We are developing a platform for discovery of RNA-targeting small molecules to treat genetic diseases, neurodegeneration and cancer. We combine a proprietary high-throughput screening platform with machine learning models and unique datasets to accelerate development of drugs for previously undruggable targets. https://wayfinderbio.com

Founded in 2010 in Seattle, WA, Westland Distillery mashes, distills, matures and bottles single malt whiskey in the heart of the Pacific Northwest with the mission of bringing a new and distinctly American voice to the world of single malt whiskey.

Know your pet's whole story with the world's leading pet DNA test. As the most accurate pet DNA test on the market, Wisdom Panel™ helps you understand your pet on a deeper level with insights into breed mix, relatives, genetic health, and physical traits. With over 20+ years of experience in genetic testing and chosen by 4+ million pet parents, Wisdom Panel delivers insights so you can give your pet the best care. Every single test contributes to the largest veterinary genetic research study to help improve the lives of all pets.

Wisecube: Revolutionizing AI Trustworthiness and Insights for Highly Regulated Industries Wisecube, founded by AI and data experts, we are a startup specializing in Open and Trustworthy AI for highly regulated industries like finance, pharma, and healthcare. Our mission is to revolutionize AI trustworthiness and insights through open-source semantic data solutions. AI has a trust problem. Hallucinations or factual inaccuracies generated by Large Language Models (LLMs) can lead to: • Stakeholder Confidence Issues: Frequent hallucinations can erode trust in AI technologies. • Compliance Violations: LLMs can perpetuate harmful stereotypes and social stigmas, potentially leading to discrimination and compliance issues. • Errors in Critical Decisions: Hallucinations can lead to erroneous decisions in critical fields like medicine, finance, and policy. The Wisecube Solution Our solution centers around the semantic modeling of data, decomposing LLM responses into semantic triplets to test the factualness of individual knowledge points. This approach provides more informative and precise insights than traditional methods that analyze paragraphs or sentences. Our Products An open-source Trustworthy AI platform that offers: • Simplified knowledge graph construction for contextual insights. • State-of-the-art open-source AI hallucination detection. • Interactive prompt engineering and active learning features. • Centralized model registry and streamlined model deployments. • Open-source API access and unified governance. • Private Cloud deployment support. Investment Highlights • Experienced team with a proven track record in AI and data science. • Addressing a critical need for trustworthy AI solutions in high-stakes industries. • Innovative technology with a strong focus on open-source collaboration. • Successful case studies demonstrating the value and impact of our solutions.

Our mission is to provide you with answers that can't otherwise be found because this information is unique to only YOU! Knowledge equals the power to work smarter and not harder; this is a key factor to achieving optimal results in any aspect of life but here at MelixGX™ it is particularly relevant to one's success in accomplishing the highest level of health, fitness, and overall well-being that many of us strive for. MelixGX™ was initially intended to focus on the fitness aspect of health and the countless number of contributing factors. These factors include the necessities (exercise regimen, diet, supplements & more) specific to every individual's body type that enable s/he to achieve their goals; our final product MelixFit™. Following this extensive research, we discovered the most common battles millions of Americans face each day, this inspired us to explore the many benefits of Cannabis. The correct strain (again, specific to one's DNA) has inimitable capabilities that include but are not limited to aiding in physical recovery, effectively and efficiently battling chronic pain, anxiety, depression, addiction, insomnia and so much more. Our final product MelixMJ™. Through sophisticated advances in technology, our knowledgeable and skilled geneticist will decode your DNA to provide you with the most analytical breakdown possible. Your DNA has all the answers, let MelixGX™ tell you what they are saying. Visit melixgx.com to learn more, and follow us on Facebook and Instagram: https://www.facebook.com/dnatestingkit/ https://www.instagram.com/melixgx/

Xylem is the global leader in advanced technologies, solutions and services that address the world's biggest water challenges. We enable our customers to dramatically improve the way water and wastewater is used, managed, conserved, re-used and returned to nature. At every level, our global team is committed to access, equity, inclusion, and diversity. Our goal is for all our colleagues to be involved, respected, valued, connected, and free to bring their authentic selves and ideas. If you are excited and passionate about solving water, we want to hear from you. #LetsSolveWater

Yakima Chief Ranches (YCR) is an integrated crop management company that specializes in breeding new hop varieties for the global brewing industry. YCR exists to create and sustain value in the hop market— from the family farm to the drinkers of great beer worldwide. The company was started in the late 1980's as three hop-farming families, the Carpenters, Smiths, and Perraults, came together to form a new hop production and research farm in the Yakima Valley under the name Yakima Chief Ranches. The late Charles "Chuck" Zimmerman was the initial breeding program director for Yakima Chief Ranches, with a directive to develop new hop varieties. Initial breeding results from the program were fruitful, leading to the selection and release of several new hop brands. The YCR breeding program joined forces with the John I. Haas, Inc. breeding program to form Hop Breeding Company (HBC) in 2003. HBC's mission is to develop pest-resistant and disease-resistant hop brands with strong commercial qualities. This hop breeding powerhouse takes advantage of the combined resources of both companies through full integration of breeding efforts. All brands from the breeding program are released jointly.

Yoneda Labs is an AI-based software company that assists chemists in optimizing reaction parameters such as temperature, concentration, and catalyst. The company's platform helps to figure out the reaction parameters without wet lab experimentation, and then can help optimize if necessary.

YouScript is on a mission to eliminate avoidable adverse drug events. Our technology synthesizes evidence impacting drug response, including pharmacogenetic testing, to support doctors and pharmacists in making faster, more proactive decisions at the point of care. We're the only clinically validated system that shows improved outcomes, reduced costs, and high patient and provider satisfaction. We're also successfully integrated into the clinical workflow of Epic, Cerner, Allscripts, PDX, and Telus Health. Equally important is that our team has a combined 100+ years of experience in pharmacogenetics, healthcare, technology development, and disruptive businesses. In pursuit of our mission, we aim to be a trusted partner to value-based healthcare organizations, providers, and payers who want to bend the healthcare cost curve with the power of precision medicine. If you are looking to be a part of the solution to solving one of the many challenges providers and patients face today, we'd love to hear from you. Whether you are a provider looking for a new clinical decision-making support tool or a potential employee looking for a new home, we can't wait to share more about what's happening at YouScript!

ZipBio is a biotech startup revolutionizing AI drug discovery with our cutting-edge protein design and drug discovery platform. We specialize in compressing biology to accelerate therapeutic innovation.